Introduction
============

Although not necessarily a new concept, since its designation by [@b72-co-2-401], evidence-based medicine (EBM) has become a watchword for the medical community. EBM is the term applied to the application of the scientific method to medical practice and involves the direct application of the best-available medical research data to clinical patient care. It requires the integration of available research evidence with clinical experience and may challenge long-standing medical traditions that have not yet been subjected to appropriate scientific scrutiny. Among clinical providers from various medical specialties there is a growing awareness of the importance of applying EBM in health care settings ([@b45-co-2-401]; [@b80-co-2-401]; [@b60-co-2-401]). Whether providers are making the transition from realization to application, however, remains equivocal ([@b14-co-2-401]) or unknown ([@b69-co-2-401]).

The emerging appreciation of EBM is also recognized within the ophthalmic literature ([@b76-co-2-401]; [@b81-co-2-401]) as well as by the [@b49-co-2-401]. The appearance of various letters to ophthalmic journal editors also suggests that clinicians realize the shortcomings inherent in the reported findings for diverse ophthalmic clinical trials involving "normal-tension" glaucoma ([@b18-co-2-401]), neovascular age-related macular degeneration ([@b78-co-2-401]), and dry eye syndrome ([@b17-co-2-401]), just to name a few. Additionally, ophthalmic investigators and providers are aware of differences that arise between analogous trials -- eg, the Ocular Hypertension Treatment Study (OHTS) ([@b53-co-2-401]) and the European Glaucoma Prevention Study (EGPS) ([@b36-co-2-401]) -- and are actively seeking to understand these differences.

However, most medical providers continue to offer clinical recommendations to patients based on didactic instruction, clinical lore, or habit because of the continuing frustration faced when trying to reconcile the necessity to review an overwhelming amount of published medical information within the time limitations of daily practice ([@b11-co-2-401]). As succinctly stated by Lee, when it comes to medical knowledge "there is simply too much to know" ([@b57-co-2-401]).

With respect to medical literature, there is a common fallacy that faces reviewers: that if a recommendation appears in print, it must be valid (ie, a form of *assumption bias* on the part of the reader). This form of bias occurs when journal reviewers under time constraints quickly scan abstracts and assume that the statements provided in the "conclusion" section must be accurate and backed up by the following pages of the article and the accompanying references (ie, *written word bias*). Another form of assumption bias may be found in the belief that the contents of expert speaker lectures or recommendations from pharmaceutical company representatives are entirely objective and lacking bias (*authority bias*).

Unfortunately, these assumptions are not always true. Although not explicitly stated during professional training, all healthcare providers are expected to provide their own self-education once they leave their institutions of graduate learning. This means continually reviewing pertinent journals, and then completing the Herculean task of critically evaluating the literature, dismissing incomplete data and applying new information directly to patient encounters. Through this process the implicit, underlying belief is that clinicians will continue to grow in knowledge, thereby becoming better, more-informed clinicians as they accumulate more clinical experience based on EBM. At no time would a medical professional be expected to be the same provider that he or she was a year previously. This would seem to be the expectations of patients as well ([@b57-co-2-401]) and enters into the controversial side issues of ongoing provider competency ([@b7-co-2-401]).

Fortunately, there are now online open-access resources available to disseminate EBM: The Cochrane Collaboration ([www.cochrane.org/index0.htm](www.cochrane.org/index0.htm)) and Bandolier ([www.jr2.ox.ac.uk/bandolier/](www.jr2.ox.ac.uk/bandolier/)), among others. Also, clinical trial registry is now required prior to publication of results of trials in some journals (<http://clinicaltrials.gov/>), which may help to prevent non-publishing of negative results of some clinical trials.

Quite simply, the consequences of failing to review the literature critically are untoward morbidity and mortality for patients. The literature is replete with examples of failed medical therapies once heralded as being definitive: intracranial-extracranial arterial bypass to reduce the risk of ischemic stroke ([@b32-co-2-401]), anti-inflammatory therapy with rofecoxib (Vioxx^®^, Merck and Co Inc, Whitehouse Station, NJ, USA) therapy ([@b16-co-2-401]), and use of oral prednisone as monotherapy in patients with optic neuritis ([@b12-co-2-401]). Chalmers statement that "One only has to review the graveyard of discarded therapies to discover how many patients have benefited from being randomly assigned to a control group" (1968) reminds us that all providers should be even more diligent about experimental therapies and critical of the results of the reports. Finally, providers cannot rely on the existing mechanisms of public oversight groups to ensure that reported clinical trial results are wholly trustworthy ([@b84-co-2-401]).

The unwritten corollary of these expectations is that clinicians will provide the ultimate control over new medical practices, procedures, and pharmaceutical products entering the health care marketplace. In other words, sceptical review of medical literature by practitioners with the null hypothesis firmly in mind (ie, there is no difference between treatment groups) and assessing the consistency of results with personal observations would satisfy the demands of EBM and avoid introduction of sub-optimal treatments and agents into daily practice. However, practitioners continue to make clinical recommendations based on peer consultation, expert opinion provided at continuing medical education conferences, or (as can be the case with pharmaceutical agents) based on data provided by representatives of pharmaceutical corporations.

The business of pharmaceutical clinical trials
==============================================

To understand the impetus behind this process, practitioners must realize the financial implications of bringing a new pharmaceutical agent to the marketplace. The estimated cost for the discovery, development, experimental trial and introduction of a single, new, successful drug to the marketplace ranges from approximately €277 million (\$390 million; [@b54-co-2-401] \[estimates updated to 2007 values via inflation calculator\]) to €568 million (\$800 million; [@b66-co-2-401]). Of this total, slightly less than 50% is incurred in the execution of clinical pharmaceutical trials ([@b54-co-2-401]).

In terms of global expenditures for pharmaceutical research and development, the top fifty pharmaceutical companies on the planet spent an estimated €62 billion in 2006 alone ([@b64-co-2-401]). In order to provide a broader frame of reference, bear in mind that this sum for research and development expenditures would rank the pharmaceutical industry number 56 out of 180 in a world ranking of countries by Gross Domestic Product ([@b50-co-2-401]).

By contrast, publicly-funded (government) spending on pharmaceutical research lags considerably behind private sector spending. The US government invested approximately €7 billion (\$10 billion) per year in pharmaceutical research and development in the 1990s ([@b26-co-2-401]), and the EU estimates for pharmaceutical research funding was expected to be approximately €0.5 billion per year between 2002 and 2006, which represented a doubling of expenditures over the previous four years ([@b35-co-2-401]). Contrast these figures to the €21 billion (\$29.9 billion) spent annually on pharmaceutical promotion to the public via direct-to-consumer campaigns ([@b30-co-2-401]). In summary, an enormous amount of money is spent each year on pharmaceutical research and private industry is funding the bulk of it.

Literature review
=================

Within this environment of colossal financial pressure to realize returns on investments, the potential for bias in pharmaceutical trial conduct and reporting remains real and is recognized in the medical literature ([@b6-co-2-401]; [@b59-co-2-401]). Thus, the pertinent question remains: how can clinicians obtain objective knowledge regarding novel pharmaceutical agents? The answer, of course, is by developing an awareness of this problem and addressing it through continuous, careful review of medical literature. Again, formal training for healthcare providers offers very little in the way of teaching methods for critical literature review, which is necessary to achieve this end. Furthermore, with the explosion of medical research publication that was taking place by the 1980s, it became clear that providers were unable to keep up with the deluge of new information that they were facing. Across all medical disciplines over 11 million randomized controlled trials had been recorded via MEDLINE by 2001 ([@b88-co-2-401]).

More germane to eye care, according to MedBioWorld there are more than 80 journals dedicated exclusively to eye and vision research (2007). In 2006 the Cochrane Eyes and Vision Group tallied more than 5,000 ophthalmic clinical trials in just 7 different ophthalmic journals accounting for 125 years of cumulative publications; while in 2004 alone, there were 1,919 articles published in 4 leading ophthalmology journals ([@b56-co-2-401]).

In order to provide some structure to clinical trial review, various medical journals have provided methods for systematic literature reviews with the goal of teaching these techniques to their readers ([@b37-co-2-401]; [@b73-co-2-401]; [@b41-co-2-401]; [@b51-co-2-401]). These reviews provide good points of departure when learning or teaching critical literature review.

Statistical discussions contained in clinical trial reports can also appear overwhelming. Not all clinicians can hold advanced mathematics degrees in statistics in order to fully interpret the significance of applied methods for Cox regression models, paired-eye correlation techniques, and non-parametric bootstrap procedures (examples from only the [@b4-co-2-401]); however, distilling the presented trial data into useful clinical information is an EBM skill incumbent upon all providers. Number-needed-to-treat analysis is a relatively straightforward mathematical application to help clinicians who are non-statisticians ([@b63-co-2-401]).

A general framework for critically appraising any clinical trial can be organized under four general headings: (1) has the study been appropriately designed? (2) Have the study results been correctly analyzed? (3) Have the study results been interpreted correctly? (4) Can the study results be applied to the patients in the reviewer's practice? ([@b51-co-2-401]). A more detailed summary of questions to ask when reviewing pharmaceutical (or other clinical) trial data is provided in [Table 1](#t1-co-2-401){ref-type="table"}. For further in-depth discussions of the specifics of clinical trial design (ie, randomization schemes, determination of *n* values, alpha calculations, statistical power, etc) please consult appropriate references.

Clinical trial validity and bias
================================

When assessing EBM, reviewers of clinical trial data must consider internal and external validity of the clinical trial results. When *internal validity* is met, readers can be assured that the study has truly examined what it set out to measure. The majority of the questions in [Table 1](#t1-co-2-401){ref-type="table"} address this component. *External validity* is the ability to generalize findings from the study cohort to the general population and will be discussed in turn.

In order to determine study validity, readers must first consider potential sources of error in the study. Essentially all medical studies contain varying degrees of *bias* ([@b43-co-2-401]), which is considered to be: "any trend in the collection, analysis, interpretation, publication or review of data that can lead to conclusions that are systematically different from the truth" (US [@b20-co-2-401]). The presence of bias is controlled via careful study design and statistical analysis; however the complete elimination of all forms of bias may still be unattainable. The presence of bias does not automatically imply that the study results should be disregarded, however, the final acceptance of study results ultimately resides with the reader, who must balance potential sources of bias against their possible impact on the recommendations and conclusions of the authors, and secondary interpretations by experts. Once more, the onus for change in clinical practices based on EBM lies with the provider.

There are over one hundred recognized types of bias in the medical literature ([@b10-co-2-401]). Although there is no consensus regarding a set number of "major" sources of bias, experimental errors can be loosely considered to occur during three periods: before the study begins (*selection bias*), while the data is being collected during the study (*information bias*), and after the conclusion of the study period when data interpretation occurs (*interpretation bias*). (For further discussion regarding sources of research bias see also: [@b71-co-2-401]; Grimes and Schultz 2002; [@b22-co-2-401], among many others.) For ophthalmic pharmaceutical trials, careful attention must be paid to the effects of selection bias and will be the focus of the following discussion. Specifically, a review of patient selection criteria, standards of comparison, and meeting well-defined endpoints are areas of potential selection bias in some ophthalmic clinical trials.

Patient selection
=================

Based on a review of existing literature, the issue of bias in patient recruitment for inclusion into ophthalmic studies has not been directly addressed. Nor have the effects of *volunteer bias* (study volunteers tend to be healthier than non-participants and may exhibit outcomes unlike other subjects) or study remuneration (another form of volunteer bias) for participation in ophthalmic studies.

Patient recruitment
===================

Bias in the recruitment of controls for comparison to affected study participants would not seem to be an issue for many advanced-stage ophthalmic pharmaceutical trials. Presumably because at this point in the process (ie, Phase 3 trials in the US), investigational medications are typically used only on those patients who already manifest a given condition for which there is no definitive treatment (ie, healthy human subjects in a control group are not given experimentally-induced choroidal neovascular membranes or intraocular pressure increases in order to test efficacy of experimental pharmaceutical agents). In general, these trial subjects are recruited directly from patient encounters in participating study sites as they are diagnosed clinically, and appropriate randomization schemes are used to prevent unexpected differences between cohorts. However, reviewers should be aware that there are many industry-sponsored pharmaceutical trials that actively recruit patients and remunerate for their participation ([@b19-co-2-401]). The reader is left to attend to study sponsorship and to discern whether volunteer bias could account for small discrepancies in reported treatment effects.

In one of the first efficacy studies for olopatadine hydrochloride (Patanol^®^), patients with a prior history of active allergic conjunctivitis were required to have positive dermatological (skin prick), serological (radioallergosorbent test \[RAST\]), or conjunctival test for enrolment into the study ([@b2-co-2-401]). To remain enrolled in the study, participants were required to have a positive conjunctival allergen challenge (CAC) at subsequent visits. CAC testing requires provocative inoculation of eyes with increasing allergenic inoculations, assessing for allergic responses, and then evaluating ocular responses to trial medications ([@b1-co-2-401]). CAC testing provides highly reproducible results and has been used frequently when studying groups of human ocular allergies ([@b40-co-2-401]), although questions remain regarding individual responses ([@b5-co-2-401]) and use of rescue medications and quality of life issues (Radcliff et al 2006). Few clinicians have direct clinical experience with CAC testing and may be left with lingering questions regarding the generalised applicability of CAC testing and the results of such trials. The result may be reliance on the opinions of others. However, clinicians are reminded that questions regarding patient recruitment, olopatadine and EBM have not been definitively answered in the literature (especially with respect to a gold standard for allergic conjunctivitis discussed below).

Eligibility (inclusion and exclusion) criteria
==============================================

Ophthalmic providers must recognize that certain inclusion and exclusion criteria for clinical trials may create other forms of internal bias that can affect external validity of reported results. This in turn may explain differences between the responses of patients reported in studies to those observed in non-study site clinics (ie, a failure to demonstrate external validity). Unfortunately, there are many ophthalmic clinical trials that leave unanswered questions for the reader to ponder.

For example when considering a study of ocular hypertension or open-angle glaucoma (OAG), there is a question as to whether the inclusion of patients with secondary open-angle glaucoma forms (eg, pseudoexfoliation \[PXG\] or pigmentary dispersion glaucoma \[PDG\]) affect the outcomes. When exact etiologies remain unknown, reviewers cannot be certain that it will not. Furthermore, results from one racial population may not necessarily translate to similar findings in other racial groups.

In neovascular age-related macular degeneration (AMD), questions remain as to whether occult, classic, and mixed forms of choroidal neovascular membranes (CNVM) follow the same natural progression. Conversion between types is known to occur. Conversely, do patients with recurrent choroidal revascularization respond differently to an intervention than those with primary lesions? Clinical experience suggests that they do in some cases.

For ophthalmic complications of diabetes mellitus, the question arises as to whether patients in a study of clinically-significant macular oedema (CSME) respond differently than those with non-CSME. Perhaps more to the point, why treat those patients previously described as being "non-clinically significant"? In addition, it is not clear whether subjects will have equivalent responses to a treatment if there is an ischemic macula versus a normally-perfused macula, and what if those patients retain good visual acuity at the outset? Does the duration of the macular oedema affect the outcomes?

Finally, can the results of a study targeting primarily female patients be applied to a clinical population which also includes males, or even predominantly males as in the case of an American Veterans' Health Administration eye clinic?

Specific examples of these types of potential selection bias regarding eligibility criteria observed in ophthalmic studies are presented in [Table 2](#t2-co-2-401){ref-type="table"}. Certainly other questions that arise from clinical trial review exist as well. It is also important to bear in mind that most patients in these studies were excluded from having other ocular co-morbidities such as cataracts, subnormal vision, prior ophthalmic surgeries, and the like. Patients with co-morbid conditions may or may not respond to treatments in the same way, further questioning the issue of external validity of the studies. While generalization from single morbidity patients to co-morbid ones has been discussed in other medical disciplines (eg, primary care) ([@b39-co-2-401]), to date it has not been directly addressed for ophthalmic patients.

If the natural courses of the disease for subtypes of patients are etiologically identical, then it is acceptable to combine sub-groups for statistical analysis. However, the authors should point out these differences (if they exist) and, likewise, the reader should be aware that these differences could influence the stated findings and explain differences between reported and observed outcomes. Consider the combination of CNVM data from AMD and Myopia in the [@b86-co-2-401]; and question whether it would also be appropriate to apply these results to cases of idiopathic CNVM.

The review of medical literature suggests other problems inherent in patient selection: failure of study investigators to invite eligible patients to participate in studies ([@b8-co-2-401]), potential influencing of patients by investigators toward inclusion/exclusion from a study ([@b33-co-2-401]), or exclusion of potential subjects due to socioeconomic factors ([@b68-co-2-401]), just to mention a few. Readers should be aware of these, and other, potential shortcomings and carefully examine the methods of recruiting patients for entry into clinical trials.

Standards of comparison
=======================

When considering the performance of a pharmaceutical agent, a proper frame of reference must be utilized by study investigators. Reviewers of clinical trials should be aware when studies lack solid standards of comparison or when other factors cloud direct comparisons between groups. It is also worthy of note that not all trials that define the same clinical endpoint are identically designed, so direct comparison of resultant findings can be potentially misleading. Additionally, trials assessing the same outcomes may include patients at different stages of the disease. In sum, the study must not compare metaphorical "apples" to "pears".

Insufficient patient numbers
----------------------------

Strength of clinical trial results often depends on the number of study subjects. Insufficient patient numbers lead to weak associations; too many patients no longer adds to statistical power. In general, the number of patients enrolled in a study is based upon the suspected treatment effect (ie, if investigators expect a 20% difference between groups, then x number of patients are recruited; if the expectation is 30%, then y number of patients are enrolled, and so on). In general, the narrower the expected treatment margin, the larger the number of patients required to statistically demonstrate that difference ([@b13-co-2-401]). Because of the variance in disease incidences, there is no accepted minimum number of patients required in order to statistically power a study. For pharmaceutical trials, the US Food and Drug Administration (FDA) recommends that Phase 3 trials (ie, those designed to ensure safety and efficacy before pharmaceutical release for use by the general population) enrol "several hundred to several thousand" patients ([@b38-co-2-401]) to ensure validation of clinical trial data. Because of the strict controls involved in these trials, Phase 3 trials results should be rigorously scrutinized, and their outcomes seriously considered, prior to the integration of a new agent into clinical practice. Conversely, readers should be aware that Phase 3 trials are also industry-sponsored and that some Phase 3 data remain unpublished and tightly guarded due to proprietary interests (yet another source of potential bias).

When studies fail to enrol a significant number of patients, then small differences in study groups can lead reviewers to question slim margins of successful treatment. There are many pharmaceutical studies with low numbers of participants. The Phase 3 study for Patanol^®^ enrolled 169 patients in three arms ([@b2-co-2-401]), whereas the [@b89-co-2-401] examined 120 patients in two arms and the [@b25-co-2-401], not a Phase 3 pharmaceutical study) enrolled 140 patients in 2 trial arms. Readers should bear in mind that the *n* value represents the total number of study participants (or eyes, depending on the study), and that the final number of patients in each arm of the study will be reduced accordingly.

Failure to compare against the "gold standard"
==============================================

If a new therapeutic agent is recommended for integration into current disease management plans, how can clinicians be assured that the recommendation is valid if the agent in question has not been compared against the *gold standard* treatment for that condition? Originally, the term gold standard applied to a diagnostic test that was considered to be definitive in its determination of a condition. However, in more recent times, the phrase has come to represent any medical benchmark (clinical outcome, diagnostic test, biopsy, chronic disease index, medication, autopsy, etc) against which new procedures and tests can be measured. There are many ophthalmic gold standards ranging from clinical testing for malingering ([@b44-co-2-401]) and automated perimetry for glaucoma ([@b83-co-2-401]) to computerized tomography for suspected orbital fractures ([@b28-co-2-401]) and reference stereo photographs for grading diabetic retinopathy ([@b91-co-2-401]). In essence, ophthalmic providers are well aware of certain clinical practices against which others are compared.

This being the case, a gold standard retains its place of prominence until a new test, medication, or procedure challenges its status and there is widespread confirmation via research data that there is a new gold standard. Unfortunately, there is no governing medical body to oversee these transitions and the metamorphosis may take years for providers (consider the apparent low impact of the results of the optic neuritis treatment trial \[[@b87-co-2-401]\]). With regard to pharmaceutical agents, in the absence of a widely-accepted gold standard, researchers may need to compare an intervention to nothing (ie, the natural course of the disease) or a placebo, which will be discussed below. [Table 3](#t3-co-2-401){ref-type="table"} lists a few studies that have abandoned important ophthalmic gold standards.

Readers should also be aware of the importance of unexpected findings when head-to-head comparisons with gold standards do periodically occur. In the only randomized clinical trial of an ophthalmic fourth-generation fluoroquinolone since US approval in 2003, moxifloxacin (Vigamox^®^, Alcon Research LTD, Fort Worth, TX, USA) was found to be an equivalent -- but not superior -- therapy for bacterial corneal ulcers when compared to the anti-bacterial gold standard: fortified topical anti-bacterial solutions or an older amino-glycoside ([@b27-co-2-401]).

The results of the only study comparing olopatadine hydrochloride to a mild ophthalmic steroid showed superiority of olopatadine; however, the comparison was not made to a classic corticosteroid like dexamethasone, fluorometholone or prednisolone, but rather to a newer, ophthalmic corticosteroid, loteprednol etabonate (Lotemax^®^, Bausch and Lomb, Tampa, FL, USA; [@b15-co-2-401]). Prior to the introduction of olopatadine, gold standard treatment for allergic conjunctivitis was single-action ophthalmic antihistamine or steroid eye drops ([@b79-co-2-401]).

In the case of CNVM related to AMD, neither verteporfin, pegaptanib, ranibizumab or bevacizumab have been compared to thermal laser photocoagulation, the previous gold standard for these cases. Interestingly, when sub-macular surgery was compared to laser photocoagulation no advantage to incisional surgery was found, the negative results were reported ([@b82-co-2-401]), and interest in the procedure waned as should be expected.

However, reviewers are left to wonder why the antibacterial comparison to the gold standard was so slow in coming and why the anti-allergy trial did not compare the study medication to the older gold standard. Neither of these questions remains answered. Even bigger questions remain regarding why ophthalmic practitioners so quickly converted prescribing patterns in favor of the newer medications.

Failure to compare to placebo
=============================

The placebo effect on medical studies has been well documented for many years, yet it remains poorly understood and its overall effect varies among trials. However, the inherent problems in comparing a pharmaceutical agent to baseline performance (ie, nothing) are also widely recognized and the failure to include placebo control may introduce a significant source of bias to study outcomes. An excellent example of the failure to include placebo control is the Ocular Hypertension Treatment Study (OHTS, [@b53-co-2-401]). OHTS investigators were attempting to compare the treatment of ocular hypertension to controls who received no placebo treatment. Because the results of this study were not unequivocal, a reviewer must ask if the results had been different (or the treatment effect even narrower than what was reported) had the control group received placebo treatment. The lack of placebo control leaves room for doubt in the results of a clinical trial that has generated so much attention since its publication.

There is cause for concern when pharmaceutical studies for bacterial keratitis are not placebo-controlled. Although terminology is likely a barrier to understanding in this instance (ie, superficial keratitis versus corneal ulceration, or the use of the term "microbial" keratitis, requiring readers to determine which microscopic organism is being discussed), it is generally conceded that non-ulcerative bacterial keratitis (ie, a mild superficial keratitis) is a self-limiting condition ([@b23-co-2-401]; [@b77-co-2-401]; [@b34-co-2-401]). Readers should be wary of lack of placebo control in some of these studies when reviewing head-to-head comparisons of anti-bacterial agents. Unfortunately, Phase 3 clinical trial data for fourth generation fluoroquinolones are not available for review in the public domain (per personal correspondence to both Allergan and Alcon Research LTC).

In anti-bacterial studies that are placebo-controlled, reviewers must also weigh slight reductions in duration of ocular symptoms against contributions to increasing bacterial resistance to anti-bacterial therapy. Finally, when comparing against gold standards, readers should be aware that MIC~90~ (minimum inhibitory concentration required to inhibit 90% of bacterial isolates) values do not significantly differ among ophthalmic fluoroquinolones and are far exceeded in current drug delivery methods (see [@b55-co-2-401], for further discussion of this important issue).

Confounders
===========

Reviewers of studies must be wary of potential confounders that may influence published results. Confounders are sources of error that occur when a factor other than the exposure of interest affects the result of the study ([@b46-co-2-401]). In other words, these are factors that have not been controlled for via study design and which may lead to faulty causation. Readers cannot be sure if the reported effect was a direct result of the study intervention or an indirect result of the confounder, especially when reported treatment effects are narrow.

Examples of potential confounders in ophthalmic studies include the concurrent use of Centrum^®^ (Whitehall-Robins Healthcare, Madison, NJ, USA) multivitamin and mineral supplements with the study formulation in the [@b3-co-2-401], allowance of verteporfin therapy before and during the pegaptanib Phase 3 trial for neovascular AMD ([@b42-co-2-401]), or the use of verteporfin therapy during the Phase 3 MARINA study of ranibizumab ([@b70-co-2-401]).

In the case of the AREDS study, how can the reviewer be certain that the Centrum supplements were not responsible for the mild, reported treatment effect and not the study medication? In the cases of pegaptanib or ranibizumab can we be certain that the observed effect was due to the investigational medication or a delayed response to verteporfin (or, if the study medications are more effective, then what becomes the new gold standard?). If these potential confounders are not sufficiently explained by the investigators, then readers are left to question the veracity of the reported conclusions found in the abstracts.

Study endpoints
===============

A crucial factor to consider in all medical research is the definition of study endpoint. Since very few ophthalmic conditions are reported in terms of "cure rates" or "prevention rates," investigators must pre-determine endpoints for research with finite temporal limits. From the standpoint of study design, research endpoints should be succinctly defined, reproducible, and appropriate to the hypothesis. Literature reviewers must ask themselves "did the endpoint(s) answer the original question?" Failure to report results in terms of primary outcomes represents a failure of a study to provide meaningful clinical information, and calls into question the original study hypothesis. It is also helpful to see outcomes written in terms of null hypotheses, but often readers are left to deduce this for themselves.

More to the point, however, reviewers must ask themselves a more clinically-relevant question regarding a study, namely: does the study ask a clinically-useful question? If a pharmaceutical trial is addressing a clinical entity like bacterial conjunctivitis, which is described as a self-limiting condition, and which is difficult to definitively diagnose without point-of-care testing, then perhaps it is more pertinent to question whether the self-limiting condition needs any active pharmaceutical agent at all, rather than assessing whether the medication resolves the condition. Even more basic to this discussion is the questions of whether there is any such thing as a 'garden variety' bacterial conjunctivitis. Although usually explicitly stated, there is another germane clinical question for readers to consider for an antibacterial ophthalmic medication: is in vitro data applicable to in vivo clinical settings? This is another test of external validity. These ideas are rarely discussed in ophthalmic anti-bacterial pharmaceutical trials, leaving the readers to wonder why.

Readers must also consider financial implications of pharmaceutical trials on their patients and society as a whole. Are the findings significant enough to justify the cost of switching to a new gold standard? As it remains incumbent upon all medical providers to consider medical costs for interventions, literature reviewers should be aware of the phenomenon of "latest-greatest" drugs. The assumption bias here is that the newest pharmaceutical agent on the market must somehow be the best. Clinically, readers need to ask more challenging questions of study reports, including whether the drug better than existing treatments and gold standards, or placebo.

This is especially important when the more inexpensive alternative may also be more efficacious. Consider the possibility of mild ophthalmic corticosteroids for the palliative relief of the symptoms of allergic conjunctivitis. Olopatadine hydrochloride costs approximately €57 (\$80) per 5 mL versus €25 (\$35) per 5 mL for generic olopatadine (available in the UK as Optanol^®^, but not yet available in the US). Then compare both of these to €14 (\$20) per 5 mL for generic fluorometholone. Two to four times as many patients can be treated with the same clinical outcome with the generic corticosteroid eye drop, however, to date, a direct comparison of these ophthalmic medications has not occurred.

Finally, medical providers should always think in terms of *functional* outcomes. Functional outcomes are those endpoints which address mortality and morbidity. Fortunately, few ophthalmic clinical trials need address mortality issues, but many ophthalmic conditions impinge on important issues of morbidity: vision loss and quality of life ([@b90-co-2-401]). Specifically, can a patient undergoing the treatment perceive an "improvement" following the intervention? Although subjective in origin, ophthalmic patients typically wish for their vision to improve back to reading/driving levels (in the cases of vitreo-retinal, lenticular, or corneal interventions, for example) or for their eyes to feel better (in the cases of conjunctivitides, uveitides, for example). Readers would always hope that study endpoints would be written to allow for functional improvements that patients can appreciate.

A shortcoming of many retinal studies is that study endpoints are defined in terms of improvement via halving of the visual angle. While statistically significant, there is considerable room for claims regarding clinical significance. Few patients seem to rave about improvements from 20/200 to 20/100 (three lines) on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts. While a statistical victory, such patients are still unable to drive or to read their mail without low vision magnification, and this calls into question the issues of both internal and external validations of study results. Pharmaceutical studies in primary open-angle glaucoma are fraught with the additional problem of a lack of early patient symptoms, making the realization of functional improvement even more difficult for study investigators to address. This may continue to be a problem until the ophthalmic community can begin reporting findings in terms of "cure rates" or "prevention rates."

Conclusion
==========

Clinical trial results that can withstand careful scrutiny by many readers may stand the test of time; however, immediate acceptance of conclusions found in abstracts may lead to erroneous generalization of study results to clinical populations. Only individual practitioners can evaluate the evidence for themselves, and the responsibility to do so remains incumbent upon them. When reviewing ophthalmic pharmaceutical trials, readers must consider the internal validity issues of patient selection, standards of comparison and study endpoints, and then determine if the study results are externally valid and can be applied to their own patient populations. The final determination regarding a switch in clinical practice to a new gold standard should be based on individual review and not on other sources. It is the intent of this article to assist practitioners in their ongoing quest to provide the best clinical care for their patients.

The views expressed in this article are those of the author and do not necessarily represent the positions of the Department of Veterans' Affairs. The author has no financial interests to disclose.

###### 

Questions to ask when reviewing a clinical trial

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Has the study been appropriately designed?**
  Who did the study?At what sites was the study performed? (ie, was it multicentered?)Who sponsored the study?What is the null hypothesis?Why is this question clinically important?Were endpoints specific and achievable?Does the study provide in vitro or in vivo data?Was the study appropriately randomized?Was there a control or gold standard group?Were study investigators and subjects double-masked?Was there an adequate sample size?Were the groups similar at the beginning of the study?Was the length of the study adequate?
  **Have the study results been correctly analyzed?**
  14\. Were all of the study subjects accounted for at the end of the study?15. What was the dropout rate for subjects?16. What were the investigators' conclusions?
  **Have the study results been interpreted correctly?**
  17\. Are the results given in terms of the stated, primary outcomes?18. Do the data agree with the conclusions?19. Are there any confounding variables?20. Do you agree with the results?
  **Can the study results be applied to the patients in the reviewer's practice?**
  21\. Should you abandon the gold standard?22. Are the results generalisable to wider populations?23. Were there any incidental findings?24. Were there any unanswered questions raised by the study?
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical studies with uncertain inclusion/exclusion criteria

  Pharmaceutical intervention            Selection criteria                                    Reference
  -------------------------------------- ----------------------------------------------------- -----------------
  Hypotensive eye drops vs surgery       Inclusion of PXG/PDG pts in OAG study                 [@b58-co-2-401]
  Laser/eye drops vs observation         Inclusion of PXG pts in OAG study                     [@b48-co-2-401]
  Ranibizumab for AMD                    Inclusion of AMD subtypes (occult, classic, mixed)    [@b47-co-2-401]
  Anecortave acetate for AMD             Inclusion of primary and recurrent CNVM               [@b75-co-2-401]
  Pegaptanib sodium for DME              Inclusion of non-CSME patients in cohort              [@b61-co-2-401]
  Bevacizumab for DME                    Inclusion of ischemic and non-ischemic maculae        [@b9-co-2-401]
  Triamcinolone acetonide for DME        Inclusion of patients with CSME of unknown duration   [@b52-co-2-401]
  Hypotensive eye drops vs observation   Incidental exclusion of non-white racial groups       [@b36-co-2-401]
  Triamcinolone acetonide for DME        Exclusion of patients with poor visual acuity         [@b29-co-2-401]
  Cyclosporine for dry eye syndrome      Exclusion of significant number of male patients      [@b74-co-2-401]

**Pharmaceuticals:** ranibizumab (Lucentis^®^, Genentech Inc, South San Francisco, CA, USA); anecortave acetate (Retaane^®^, Alcon Research LTD, Fort Worth, Texas, USA); pegaptanib sodium (Macugen^®^, \[OSI\] Eyetech Pharmaceuticals Inc, New York NY, USA); bevacizumab (Avastin^®^, Genentech Inc, South San Francisco, CA, USA); cyclosporine (Restasis^®^, Allergan, Irvine, CA, USA).

**Abbreviations:** AMD, age-related macular degeneration; CNVM, choroidal neovascular membranes; CSME, clinically significant macular oedema; DME, diabetic macular oedema; MDRSG, Macugen Diabetic Retinopathy Study Group; DRCRN, Diabetic Retinopathy Clinical Research Network; EGPS, European Glaucoma Prevention Study; OAG, open-angle glaucoma; OCT, optical coherence tomography; PDG, pigmentary dispersion glaucoma; PSG, pseudoexfoliation.

###### 

Clinical studies not addressing established ophthalmic gold standards

  Pharmaceutical intervention        Reference         Gold standard                                                            Gold standard reference
  ---------------------------------- ----------------- ------------------------------------------------------------------------ -------------------------
  Verteporfin for AMD                [@b85-co-2-401]   Thermal laser photocoagulation                                           [@b62-co-2-401]
                                     [@b85-co-2-401]   Geographical Criteria for CNVM[a](#tfn3-co-2-401){ref-type="table-fn"}   [@b62-co-2-401]
  Pegaptanib sodium for DME          [@b61-co-2-401]   CSME                                                                     [@b31-co-2-401]
  Triamcinolone acetonide for DME    [@b29-co-2-401]   OCT in lieu of CSME                                                      [@b31-co-2-401]
  Olopatadine for ocular allergies   [@b2-co-2-401]    Mild corticosteroid                                                      [@b79-co-2-401]

ie, subfoveal, juxtafoveal and extrafoveal.

**Pharmaceuticals:** verteporfin (Visudyne^®^; Novartis AG, Basel, Switzerland).

**Abbreviations:** AMD, age-related macular degeneration; CNVM, choroidal neovascular membranes; TAP, Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group; MPS, Macular Photocoagulation Study Group; ETDRS, Early Treatment Diabetic Retinopathy Study Research Group; DRCRN, Diabetic Retinopathy Clinical Research Network; CSME, clinically significant macular oedema; OCT, optical coherence tomography.
